Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC.

Mouri A, Kenmotsu H, Kagamu H, Azuma K, Saito R, Akamatsu H, Yonesaka K, Kakegawa M, Nagashima H, Takahashi S, Fujita M, Yanagitani N, Ninomiya K, Nishioka Y, Mori K, Kitano S, Tamada K, Yamamoto N, Gemma A, Mitsudomi T

Open source

DOI: 10.1158/1078-0432.ccr-25-3991
Published: 2026 Sep 1
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-3991,
  title = {Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC.},
  author = {Mouri A and Kenmotsu H and Kagamu H and Azuma K and Saito R and Akamatsu H and Yonesaka K and Kakegawa M and Nagashima H and Takahashi S and Fujita M and Yanagitani N and Ninomiya K and Nishioka Y and Mori K and Kitano S and Tamada K and Yamamoto N and Gemma A and Mitsudomi T},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-3991},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-3991}
}

RIS

TY  - JOUR
TI  - Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC.
AU  - Mouri A
AU  - Kenmotsu H
AU  - Kagamu H
AU  - Azuma K
AU  - Saito R
AU  - Akamatsu H
AU  - Yonesaka K
AU  - Kakegawa M
AU  - Nagashima H
AU  - Takahashi S
AU  - Fujita M
AU  - Yanagitani N
AU  - Ninomiya K
AU  - Nishioka Y
AU  - Mori K
AU  - Kitano S
AU  - Tamada K
AU  - Yamamoto N
AU  - Gemma A
AU  - Mitsudomi T
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-3991
UR  - https://doi.org/10.1158/1078-0432.ccr-25-3991
ER  -

APA

A, M., H, K., H, K., K, A., R, S., H, A., K, Y., M, K., H, N., S, T., M, F., N, Y., K, N., Y, N., K, M., S, K., K, T., N, Y., A, G., & T, M. (2026). Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-3991

Source records

pubmed · retrieved 2026-09-26T13:06:46.087Z